Much-efficient and cost-effective manufacturing of antibody biotherapeutics employing integrated negative chromatography technology
Lead Participant:
UCB CELLTECH
Abstract
The current platform antibody purification process deployed in the bioprocesing industry becomes less efficient and less cost-effective to match with high titre upstream technologies. Based on previous feasibility studies using model antibodies, the key aim and objective of this project is to investigate negative chromatography based technologies using real industrial feedstocks to dramatically improve the overall process efficiency issue as described above. The market size in the downstream biopharmaceutical processing sector is ca $3 - 5 billions and it is a global market to play. The successful outcomes of this project will bring enormous potential cost benefits to the industry.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
UCB CELLTECH | £881,664 | £ 440,832 |
  | ||
Participant |
||
CELLTECH R&D LIMITED | ||
BIOTOOLOMICS LIMITED | £466,174 | £ 279,704 |
INNOVATE UK |
People |
ORCID iD |
Mariangela Spitali (Project Manager) |